Close Menu

NEW YORK (360Dx) – CareFirst BlueCross BlueShield is looking to grow a new program aimed at helping diagnostic companies obtain insurance coverage for new tests.

The program, called HealthWorx, began operation in late August with a partnership with Exosome Diagnostics, a company developing exosome-based biofluid diagnostic tests. That partnership has already resulted in a completed 500-patient evidence development study of ExoDx's prostate cancer diagnostic, the ExoDx Prostate IntelliScore, or EPI Test, according to executives at CareFirst and ExoDx.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Sponsored by

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.